LENZ Therapeutics (LENZ) Retained Earnings (2020 - 2026)
LENZ Therapeutics (LENZ) reported Retained Earnings of -$268.6 million for Q1 2026, down 218497.56% year-over-year from N/an in Q1 2025, and down 18.27% on a QoQ basis from -$227.1 million in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Retained Earnings data on file, last reported at -$268.6 million in Q1 2026.
- Quarterly Retained Earnings fell 218497.56% year-over-year to -$268.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$268.6 million (down 218497.56% YoY) and the FY2025 annual result came in at -$227.1 million, down 56.63% from the prior year.
- Retained Earnings fell to -$268.6 million in Q1 2026 per LENZ's latest filing, from -$227.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $123000.0 in Q1 2025 and bottomed at -$344.1 million in Q3 2023.
- The 5-year median for Retained Earnings is -$174.5 million (2025), against an average of -$164.6 million.
- The widest annual swing landed in 2024, when Retained Earnings tumbled 2417000.0%; it then surged 12400.0% in 2025.
- Tracing LENZ's Retained Earnings over 5 years: stood at -$242.4 million in 2022, then jumped by 100.0% to $6000.0 in 2023, then plunged by 2417000.0% to -$145.0 million in 2024, then sank by 56.63% to -$227.1 million in 2025, then slipped by 18.27% to -$268.6 million in 2026.
- Per Business Quant, the three latest LENZ Retained Earnings figures stand at -$268.6 million (Q1 2026), -$227.1 million (Q4 2025), and -$191.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | -268.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -268.63 Mn |
| Dec 31, 2025 | -227.14 Mn |
| Sep 30, 2025 | -191.20 Mn |
| Jun 30, 2025 | -174.55 Mn |
| Mar 31, 2025 | 123,000.00 |
| Dec 31, 2024 | -145.01 Mn |
| Sep 30, 2024 | -132.40 Mn |
| Jun 30, 2024 | -122.15 Mn |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | -344.14 Mn |
| Jun 30, 2023 | -321.65 Mn |
| Mar 31, 2023 | -266.34 Mn |
| Dec 31, 2022 | -242.40 Mn |
| Sep 30, 2022 | -1.60 Mn |
| Jun 30, 2022 | -193.12 Mn |
| Mar 31, 2022 | -167.19 Mn |
| Sep 30, 2021 | -122.42 Mn |
| Jun 30, 2021 | -107.80 Mn |
| Dec 31, 2020 | -70.59 Mn |